Jerome Stevens Pharmaceuticals — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Jerome Stevens Pharmaceuticals is a niche, vertically-integrated generic drug manufacturer with a strong legacy in complex generic formulations. The company's core value proposition is an unwavering commitment to product quality over portfolio breadth, a stance it maintains as a family-owned operation. Its historic achievement was securing the first New Drug Application (NDA) approval for levothyroxine sodium (UNITHROID®) in 2000, establishing a durable branded presence within a large generic market. JSP's commercial focus remains on its two key products, UNITHROID® and Digoxin, distributed in the United States through a partnership with a major pharmaceutical distributor.

EndocrinologyCardiology

Technology Platform

Expertise in complex formulation and consistent, high-quality manufacturing of narrow-therapeutic-index (NTI) generic drugs, particularly in solid oral dosage forms (tablets).

Opportunities

Sustained, lifelong demand for levothyroxine ensures a large underlying market.

The company's position as the manufacturer of the FDA's reference listed drug for levothyroxine provides a durable branding and quality distinction in a generic market.

Regulatory focus on manufacturing quality for complex generics aligns with JSP's core competency.

Risk Factors

Extreme revenue dependence on just two products, primarily UNITHROID®.

Facing intense pricing pressure and competition from numerous generic versions bioequivalent to its own product.

Operational risk associated with manufacturing complex, narrow-therapeutic-index drugs under constant regulatory scrutiny.

Competitive Landscape

JSP competes in the massive, highly competitive generic levothyroxine market, facing numerous large generic manufacturers (e.g., Mylan, Sandoz, Lannett). Its key differentiator is UNITHROID's status as the original FDA-approved reference product, a unique branding and quality claim. In digoxin, it competes in a smaller, mature generic commodity market.

More companies in Small Molecule Drugs →More companies in United States →